



Liquidia Technologies to Report 2018 Financial Results and Provide Corporate Update on February 26, 2019

February 13, 2019

RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2019 (GLOBE NEWSWIRE) -- [Liquidia Technologies, Inc. \(Nasdaq:LQDA\)](#) ("Liquidia"), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its [proprietary PRINT® technology](#) to transform the lives of patients, today announced that 2018 financial results will be reported on Tuesday, February 26, 2019. The company will host a webcast and conference call at 8:00 a.m. ET to discuss financial results and provide a corporate update.

The live call may be accessed by dialing 1-877-707-8711 (domestic) and 1-857-270-6219 (international), and entering the conference code: 5960248. A live and archived webcast of the call will be available on the [Events & Presentations](#) page of Liquidia's website.

About Liquidia Technologies

[Liquidia Technologies](#) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its [proprietary PRINT® technology](#) to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINT® particle engineering platform: [LIQ861](#) for the treatment of pulmonary arterial hypertension and [LIQ865](#) for the treatment of local post-operative pain. Being evaluated in a Phase 3 clinical trial (INSPIRE), LIQ861 is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, palm-sized, disposable dry powder inhaler. LIQ865, for which Liquidia has completed two Phase 1 clinical trials, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. For more information visit our website at www.liquidia.com.

Contact Information

Investors:

Jenny Kobin
IR Advisory Solutions
919.328.4389
IR@liquidia.com

Media:

Christy Curran
Sam Brown Inc.
615.414.8668
media@liquidia.com



Source: Liquidia Technologies, Inc.